Glycoengineered Protein Nanoparticles for Vaccine Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rules for how immune responses specific to nanoparticle scaffolds affect the immunogenicity of displayed antigens have not been established, limiting the effectiveness of protein nanoparticle-based vaccine designs.
Innovation Solution
The development of polypeptides with specific amino acid sequences, including substitutions with sequons, which self-assemble into nanoparticles that can display antigens on their surface, and the creation of fusion proteins and nanoparticles that incorporate these polypeptides to generate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If protein nanoparticle scaffolds are used in vaccine designs, then clinical safety and efficacy are improved, but the rules for how immune responses specific to nanoparticle scaffolds affect the immunogenicity of displayed antigens are not established
Solution Approach 1:
The patent applies parameter changes by systematically varying the nanoparticle scaffold properties (size, shape, composition, surface chemistry) to establish how these parameters influence immune responses and antigen immunogenicity. This allows determination of optimal scaffold parameters that enhance vaccine efficacy while minimizing scaffold-specific immune interference.
Solution Approach 2:
The patent employs local quality by modifying specific regions of the nanoparticle scaffold (such as surface functionalization, localized antigen display patterns, or region-specific chemical modifications) to control immune recognition and improve antigen presentation without altering the overall scaffold structure.
2Adaptability or versatility
If polypeptides with sequon substitutions are developed to self-assemble into nanoparticles, then antigen display capability is improved, but the complexity of polypeptide design and assembly increases
Solution Approach 1:
The patent applies segmentation by dividing the polypeptide structure into distinct functional modules: self-assembly domains (such as coiled-coil structures or beta-sheet forming regions), sequon-containing epitope regions for antigen display, and linker regions. This modular approach simplifies design while enabling versatile antigen presentation.
Solution Approach 2:
The patent employs universality by designing polypeptide scaffolds with universal self-assembly motifs that can accommodate different antigen sequences through standardized sequon substitutions. The core assembly mechanism remains constant while allowing diverse antigen payloads, reducing design complexity.
3Reliability
If fusion proteins are created to incorporate polypeptides and generate immune responses, then immunogenicity of displayed antigens is enhanced, but the complexity of protein structure and purification increases
Solution Approach 1:
The patent applies taking out by separating the purification tag (such as His-tag or GST-tag) as a distinct removable element from the functional fusion protein. This allows easy removal of the tag after purification through affinity chromatography, simplifying the overall process while maintaining high immunogenicity.
Solution Approach 2:
The patent employs an intermediary approach by introducing flexible linker sequences (such as Gly-Ser linkers) between the polypeptide scaffold and antigen domains in fusion proteins. These linkers facilitate proper folding and assembly while providing sites for purification tags, simplifying both structure and purification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach enhances the immunogenicity of displayed antigens, improving the efficacy of nanoparticle-based vaccines by optimizing antigen presentation and immune response generation.
Implementation Method 1
The development of polypeptides with specific amino acid sequences, including substitutions with sequons, which self-assemble into nanoparticles
Implementation Method 2
nanoparticles that can display antigens on their surface
Data Source
AI summary
Polypeptides including the amino acid sequence of SEQ ID NO:78-80, substituted with one or more sequon, are provided, as are fusion proteins and nanoparticles formed from such polypeptides, and methods for their use.